Top Ten most popular articles on Pharmafile.com this week
pharmafile | September 6, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Mylan, brexit
It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on Pharmafile.com over the past seven days:
Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the EU and the economic and medical harm that would cause, it has become known that Ireland will not succumb to the same medicine access issues that threaten to affect England.
9. AstraZeneca shows off Farxiga heart failure efficacy at ESC 2019
AstraZeneca has revealed new Phase 3 data illustrating that Farxiga (dapagliflozin), in combination with standard of care, met its primary endpoint by reducing the incidence of cardiovascular death and the worsening of heart failure.
8. AZ’s Tagrisso secures China approval in first-line advanced lung cancer
AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment of locally-advanced or metastatic non-small cell lung cancer (NSCLC), it has emerged.
As the UK hurtles towards a catastrophic and autocratic exit from the European Union, the British Medical Association (BMA) has warned of the “devastating impact” a no-deal Brexit would inflict on an already underfunded NHS over the challenging winter period.
6. Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta
Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster therapy Alimta (permetrexed) for the treatment of non-squamous non-small cell lung cancer (NSCLC) and mesothelioma.
5. Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis
New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment of relapsing forms of multiple sclerosis (RMS).
4. BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the treatment of newly diagnosed glioblastoma multiforme (GBM) when combined with the current standard of care, temozolomide and radiation therapy).
AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung cancer (SCLC).
2. Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients
New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint but still presented clinical benefit compared to valsartan in heart failure patients with preserved ejection fraction (HFpEF).
1. AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk
AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that the therapy reduced the relative risk for the composite of cardiovascular (CV) death, heart attack, or stroke compared to aspirin alone.
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
